You are here
The Pricing Framework for Australian Public Hospital Services 2022–23 (the Pricing Framework) is the key strategic document underpinning the national efficient price and national efficient cost for the 2022–23 financial year.
Chimeric antigen receptor T cell therapy (CAR-T cell): guidelines for costing, counting and reconciliation of funding18 June 2020
The guidelines set out the scope, funding, costing, counting and reconciliation of funding for the chimeric antigen receptor T cell therapy (CAR-T cell) immunotherapy program using the Novartis CAR-T product Kymriah. The CAR-T program is for paediatric and young adults (up to 25 years) with Acute Lymphoblastic Leukaemia (ALL) who relapse or do not respond to initial therapy.
This document provides the technical specifications for how the Independent Hospital Pricing Authority (IHPA) developed the activity based funding models for the service streams to be funded for the National Efficient Price and the National Efficient Cost Determinations 2020–21.